Piper Jaffray Said Taspo Delays A Positive for Amylin (AMLN)
Tweet Send to a FriendGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 1
Rating Summary:
3 Buy, 8 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 1
Trade AMLN Now!
Analysts at Piper Jaffray are commenting positively on Amylin Pharmaceuticals (Nasdaq: AMLN) on Taspo delays.
The firm commented, "Roche announced this morning an amendment to their Phase III taspoglutide trial protocol to address cases of hypersensitivity reactions, which although rare (<1%) will result in a 12-18 month delay to the regulatory timeline. This emerging safety concern further supports our view that Bydureon possesses the best therapeutic profile amongst the GLP-1 class. This news should also assuage investor concerns related to sales potential of Bydureon and its ability to deliver sustainable profitability for AMLN. We expect today's news to potentially decrease launch costs of Bydureon as Amylin and Lilly will now have 3-4 years to establish the drug in the marketplace prior to taspoglutide launch, driving profitability. Taspo's delay also opens the opportunity for higher Bydureon sales. We are reiterating our Overweight rating on AMLN and expect upside in shares to be driven by confirmation of Bydureon's leading position at the ADA conference next week and potentially earlier approval."
Real-Time Market Moving News and Intelligence –Sign-Up Free Today
http://www.streetinsider.com/premium_content.php
The firm commented, "Roche announced this morning an amendment to their Phase III taspoglutide trial protocol to address cases of hypersensitivity reactions, which although rare (<1%) will result in a 12-18 month delay to the regulatory timeline. This emerging safety concern further supports our view that Bydureon possesses the best therapeutic profile amongst the GLP-1 class. This news should also assuage investor concerns related to sales potential of Bydureon and its ability to deliver sustainable profitability for AMLN. We expect today's news to potentially decrease launch costs of Bydureon as Amylin and Lilly will now have 3-4 years to establish the drug in the marketplace prior to taspoglutide launch, driving profitability. Taspo's delay also opens the opportunity for higher Bydureon sales. We are reiterating our Overweight rating on AMLN and expect upside in shares to be driven by confirmation of Bydureon's leading position at the ADA conference next week and potentially earlier approval."
Real-Time Market Moving News and Intelligence –Sign-Up Free Today
http://www.streetinsider.com/premium_content.php
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- AcelRx (ACRX) Target Lifted at Jefferies
- UPDATE: SolarCity (SCTY) on Watch as Negative Research Hits
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
Piper Jaffray
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
